文献速递胸部肿瘤

肺原位腺癌与微浸润腺癌切除术后长期预后

Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung.
PubMed 文献 · J Thorac Oncol · 2021-04-27

该研究回顾性分析1998至2010年间524例根治性切除的肺原位腺癌(AIS,207例)和微浸润腺癌(MIA,317例)患者,中位随访100个月。AIS和MIA均无复发,10年疾病特异性生存率均为100%,总生存率分别为95.3%和97.8%,10年异时性第二原发肺癌发生率分别为5.6%和7.7%,与EGFR突变状态无关。

要点

  • AIS和MIA切除术后无复发,10年疾病特异性生存率均为100%。
  • 术后10年异时性第二原发肺癌发生率分别为5.6%和7.7%。
  • AIS与MIA的长期预后极佳,支持将其与其他肺腺癌区分。

核心结论

  • AIS和MIA切除术后超过5年复发风险极低,但需注意异时性第二原发肺癌的发生。

研究设计与样本

  • 回顾性分析1998至2010年间4768例肺癌手术患者,纳入524例根治性切除的AIS(207例,39.5%)和MIA(317例,60.5%)患者。

主要发现

  • 中位随访100个月(范围1-237),AIS和MIA均无肺癌复发。
  • AIS和MIA的10年疾病特异性生存率均为100%(p=0.72),总生存率分别为95.3%和97.8%(p=0.94)。
  • AIS和MIA术后10年异时性第二原发肺癌发生率分别为5.6%和7.7%(p=0.45),与EGFR突变状态无关。

临床怎么用

  • AIS和MIA术后长期生存极好,临床可考虑适当减少随访强度,但仍需监测第二原发肺癌。

局限性

  • 回顾性单中心研究,随访时间范围较大,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The WHO classification of lung tumors defines adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) as cancers with no or limited histologic invasive components. The probability of patients with AIS or MIA being recurrence free for 5 years postoperatively has been found to be 100%. This study aimed to analyze the prognosis of patients with AIS or MIA after more than 5 postoperative years. METHODS: We reviewed the pathologic findings of 4768 patients who underwent resection for lung cancer between 1998 and 2010. Of these, 524 patients with curative resection for AIS (207 cases, 39.5%) and MIA (317 cases, 60.5%) were included. Postoperative recurrence, survival, and development of secondary primary lung cancer (SPLC) were analyzed. RESULTS: Of the included patients, 342 (65.3%) were of female sex, 333 (63.5%) were nonsmokers, and 229 (43.7%) underwent sublobar resection. Average pathologic total tumor diameter was 15.2 plus or minus 5.5 mm. Median postoperative follow-up period was 100 months (range: 1-237). No recurrence of lung cancer was observed for either AIS or MIA cases. Estimated 10-year postoperative disease-specific survival rates were 100% and 100% (p = 0.72), and overall survival rates were 95.3% and 97.8% (p = 0.94) for AIS and MIA cases, respectively. Estimated incidence rates of metachronous SPLC at 10 years after surgery were 5.6% and 7.7% for AIS and MIA, respectively (p = 0.45), and these were not correlated with the EGFR mutation status. CONCLUSIONS: Although the development of metachronous SPLC should be noted, the risk of recurrence is quite low at more than 5 years after resection of AIS and MIA. This finding strengthens the clinical value of distinguishing AIS and MIA from other adenocarcinomas of the lung.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yotsukura M, Asamura H, Motoi N, et al. Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung. J Thorac Oncol. 2021. PMID: 33915249. doi:10.1016/j.jtho.2021.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。